Giulio Massimi

Giulio Massimi

Auto-generated profile, based on publicly available information

Giulio Massimi

Department of Cardiothoracic Surgery, Heart and Vascular Centre, Maastricht University Medical Centre , P. Debyelaan, Maastricht 12–6221

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 April 2023 in Artificial Organs
Verified
Journal Article
Open access
GMGiulio Massimi
Giulio Massimi
MMMatteo Matteucci
Matteo Matteucci
MBMichele De Bonis
Michele De Bonis
MKMariusz Kowalewski
Mariusz Kowalewski
Francesco FormicaFrancesco Formica
Francesco Formica
RLRoberto Lorusso
Roberto Lorusso
Background: Post‐acute myocardial infarction papillary muscle rupture (post‐AMI PMR) may present variable clinical scenarios and degree of emergency due to result of cardiogenic shock. Veno‐arterial extracorporeal life support (V‐A ECLS) has been proposed to improve extremely poor pre‐ or postoperative conditions. Information in this respect is scarce. Methods: From the CAUTION (meChanical complicAtion of acUte myocardial infarcTion: an InternatiOnal multiceNter cohort study) database (16 different Centers, data from 2001 to 2018), we extracted adult patients who were surgically treated for post‐AMI PMR and underwent pre‐ or/and postoperative V‐A ECLS support. The end‐points of this study were in‐hospital survival and ECLS complications. Results: From a total of 214 post‐AMI PMR patients submitted to surgery, V‐A ECLS was instituted in 23 (11%) patients. The median age was 61.7 years (range 46–81 years). Preoperatively, ECLS was commenced in 10 patients (43.5%), whereas intra/postoperative in the remaining 13. The most common V‐A ECLS indication was post‐cardiotomy shock, followed by preoperative cardiogenic shock and cardiac arrest. The median duration of V‐A ECLS was 4 days. V‐A ECLS complications occurred in more than half of the patients. Overall, in‐hospital mortality was 39.2% (9/23), compared to 22% (42/219) for the non‐ECLS group. Conclusions: In post‐AMI PMR patients, V‐A ECLS was used in almost 10% of the patients either to promote bridge to surgery or as postoperative support. Further investigations are required to better evaluate a potential for increased use and its effects of V‐A ECLS in such a context based on the still high perioperative mortality.

MGMirosław Andrzej Gozdek
Mirosław Andrzej Gozdek
ŁKŁukasz Kuźma
Łukasz Kuźma
EDEmil Julian Dąbrowski
Emil Julian Dąbrowski
MJMichał Janiak
Michał Janiak
MPMartyna Pietrzak
Martyna Pietrzak
Mariusz KowalewskiMariusz Kowalewski
Mariusz Kowalewski
Background: Transcatheter aortic valve implantation (TAVI) has become a broadly acceptable alternative to AV surgery in patients with aortic stenosis (AS). New valve designs are becoming available to address the shortcomings of their predecessors and improve clinical outcomes. Methods: A systematic review and meta-analysis was carried out to compare Medtronic’s Evolut PRO, a new valve, with the previous Evolut R design. Procedural, functional and clinical endpoints according to the VARC-2 criteria were assessed. Results: Eleven observational studies involving N = 12,363 patients were included. Evolut PRO patients differed regarding age (p < 0.001), sex (p < 0.001) and STS–PROM estimated risk. There was no difference between the two devices in terms of TAVI-related early complications and clinical endpoints. A 35% reduction of the risk of moderate-to-severe paravalvular leak (PVL) favoring the Evolut PRO was observed (RR 0.66, 95%CI, [0.52, 0.86] p = 0.002; I2 = 0%). Similarly, Evolut PRO-treated patients demonstrated a reduction of over 35% in the risk of serious bleeding as compared with the Evolut R (RR 0.63, 95%CI, [0.41, 0.96]; p = 0.03; I2 = 39%), without differences in major vascular complications. Conclusions: The evidence shows good short-term outcomes of both the Evolut PRO and Evolut R prostheses, with no differences in clinical and procedural endpoints. The Evolut PRO was associated with a lower rate of moderate-to-severe PVL and major bleeding.

1 May 2022 in Annals of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
GMGiulio Massimi
Giulio Massimi
MMMatteo Matteucci
Matteo Matteucci
MKMariusz Kowalewski
Mariusz Kowalewski
DRDaniele Ronco
Daniele Ronco
GCGiovanni Chiarini
Giovanni Chiarini
RLRoberto Lorusso
Roberto Lorusso
Severe mitral regurgitation secondary to papillary muscle rupture is one of the mechanical complications after an acute myocardial infarction. Surgical strategies represent the cornerstone of treatment in this disease; in addition to surgical valve replacement, approaches involving surgical valve repair have been reported over time in different clinical scenarios to restore valve competency, improve cardiac function and reduce mechanical prosthesis-related risks. Moreover, in recent years, percutaneous trans-catheter procedures have emerged as an important alternative in high risk or inoperable patients.

25 November 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
PDF file
DRDaniele Ronco
Daniele Ronco
MMMatteo Matteucci
Matteo Matteucci
GMGiulio Massimi
Giulio Massimi
Michele Di MauroMichele Di Mauro
Michele Di Mauro
RLRoberto Lorusso
Roberto Lorusso
Click on the article title to read more.

22 August 2025 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
GMGiulio Massimi
Giulio Massimi
MMMatteo Matteucci
Matteo Matteucci
MBMichele MDB De Bonis
Michele MDB De Bonis
MKMariusz Kowalewski
Mariusz Kowalewski
Francesco FormicaFrancesco Formica
Francesco Formica
RLRoberto Lorusso
Roberto Lorusso
Objectives: Papillary muscle rupture (PMR) is a rare but potentially fatal mechanical complication after acute myocardial infarction (AMI). Although surgery is considered the gold-standard treatment for post-AMI PMR, the optimal surgical strategy remains unclear. Methods: Data from post-AMI PMR patients submitted to mitral valve replacement (MVR) or mitral valve repair (MVr) surgery in the period between 2001 and 2019, from 20 international centres, were collected in the CAUTION study database. In-hospital and long-term post-discharge mortality were the endpoints. A multivariable logistic regression model was used to determine mortality independent factors. Results: The patient cohort available included 218 patients. MVR was the most frequent type of surgery (81.6%). Complete PMR was more common in the MVR group (71.9%, P = .008), while partial PMR was more frequent in MVr patients (75%, P = .008). In-hospital mortality rate was 25.8% in the MVR subgroup and 20% in MVr subjects (P = .440). In MVR subgroup, concomitant coronary artery bypass grafting (CABG) was associated with lower in-hospital mortality (n = 20/96, 21%) than no concomitant CABG (31.7%, P = .035). Survival at 1, 3, 5, and 10 years was 59.3%, 55.9%, 53.1%, 46.9% in the MVR group and 59.9%, 56.8%, 54.1%, and 43.2% in MVr patients, respectively, with no statistical differences (P = .474). Patients underwent MVr surgery, and 1-, 3-, 5-, and 10-year survival was 79.8%, 75.4%, 68.5%, and 37.5%, respectively, when CABG revascularization was performed, while no CABG survival was 16.7%, 16.7%, 8.3%, and 8.3% (P < .001). Conclusions: MVR is the most commonly performed in complete post-AMI PMR and MVr in partial PMR. No differences were observed regarding in-hospital and long-term mortality in the 2 surgical groups, and no independent factors were associated with overall mortality. Concomitant CABG was associated with higher in-hospital survival. Clinical Registration Number: Clinicaltrials.gov, NCT03848429.

11 May 2026 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
RLRoberto Lorusso
Roberto Lorusso
MMMatteo Matteucci
Matteo Matteucci
DRDaniele Ronco
Daniele Ronco
GMGiulio Massimi
Giulio Massimi
SPSusanna Price
Susanna Price
NBNikolaos Bonaros
Nikolaos Bonaros
The prevalence of mechanical complications following acute myocardial infarction has steadily declined in recent years owing to advances in prompt coronary revascularization, and they now occur in <1% of acute myocardial infarction cases. Nevertheless, significant haemodynamic impairment may already be present at hospital admission, requiring immediate diagnostic evaluation and urgent intervention. Until recently, surgical repair was the only treatment option, with non-negligible in-hospital mortality rates, particularly among patients with acute cardio-circulatory failure. Advances in transcatheter percutaneous procedures have now introduced alternative treatment strategies, especially for high-risk or inoperable patients. Recurrence of post-acute myocardial infarction mechanical complications, even shortly after the repair of the underlying lesion, has a critical impact on patient outcome and underscores the need for careful monitoring during hospitalization as well as after discharge. The role of concomitant coronary revascularization remains controversial, with variable effects on both early and late outcomes, and warrants further investigation. Temporary mechanical circulatory support has shown encouraging results, either for pre-procedural haemodynamic stabilization (‘bridge-to-procedure’) or for prophylactic, extended peri-procedural support to facilitate myocardial recovery (‘bridge-to-recovery’). Optimal management should be guided by a multidisciplinary Heart Team approach (including Shock Team involvement where appropriate) with integration of palliative care into the decision-making process.